Colorado has specified state personal-use protections for adults aged 21 and older and a separate regulated, supervised-services framework. These are different legal categories.
Personal-use protections do not create a general retail market. Public consumption and impaired driving remain prohibited.
The August 2026 law provides for limited regulated transactions associated with supervised administration at licensed premises; it does not create general take-home or online retail sales.
Psilocybin remains a Schedule I controlled substance under federal law, regardless of the state framework.
Implementation details and individual license availability were not verified. The legal framework is not a finding of eligibility or availability.
This finder currently reviews the Oregon and Colorado state frameworks. It does not determine the rules for another state, territory or city.
Psilocybin remains a Schedule I controlled substance under federal law.
Local enforcement or decriminalization policies do not by themselves establish state-law or federal permission, retail legality, or authorization to travel with a substance.
Consult current official state and local information for an unreviewed location. No permission is inferred from a missing entry.
Listed hallucinogenic mushrooms are prohibited under the Opiumwet. Reviewed official records distinguish sclerotia, often called magic truffles, from those mushrooms.
A ministerial answer distinguishes sclerotia from prohibited mushrooms. A 2024 tax judgment discusses untreated sclerotia separately from controlled preparations; the Supreme Court dismissed the tax appeal in April 2026.
That distinction is not a blanket legal determination for capsules, extracts, other preparations, medical services or cross-border activity.
The consolidated Opiumwet effective 17 September 2026 was reviewed on 19 September 2026. The cited court proceedings concern VAT; they do not establish permission for a particular product, preparation, service or cross-border activity.
Production, sale and possession of psilocybin are generally illegal without authorization. Canada has limited, case-specific medical and research pathways.
Health Canada describes clinical trials, the practitioner-requested Special Access Program and individual Controlled Drugs and Substances Act exemptions.
These pathways do not establish general retail permission or determine whether an individual qualifies.
The presence of a shop or an online offer does not establish authorization. This is information about the framework, not a medical recommendation.
Australia permits a limited medical pathway involving specifically authorized psychiatrists and psilocybin for treatment-resistant depression. It is not general retail access.
The framework requires relevant approvals and supervised administration in a health setting. Patients cannot take the product home.
Other uses remain subject to Schedule 9 controls and applicable research exceptions. State and territory requirements also apply.
This overview is educational and does not assess treatment suitability, recommend use or identify a prescriber. The products remain unapproved therapeutic goods.
